Background and Aims: Gastric outlet obstruction (GOO) is a late complication of several malignancies, markedly impairing quality of life. Surgical gastroenterostomy (S-GE) has long been the palliative standard, but outcomes are variable and morbidity remains considerable. Endoscopic ultrasound-guided gastroenterostomy (EUS-GE) has emerged as a minimally invasive alternative. We conducted a systematic review and meta-analysis comparing EUS-GE and S-GE, with a specific focus on malignant GOO. Methods: MEDLINE, Embase, Scopus, and the Cochrane Library were searched through September 2025. Eligible studies directly compared EUS-GE and S-GE and reported clinical success (CS), adverse events (AEs), severe AEs, and recurrence/reintervention. Pooled odds ratios (OR) with 95% confidence intervals (CI) were calculated using random-effects models. Results: Thirteen studies (2 RCTs, 11 retrospective; 1,611 patients) were analyzed. Overall, EUS-GE achieved higher CS (OR 2.69; p=0.007), fewer AEs (OR 0.21; p<0.001) and severe AEs (OR 0.54; p=0.05) versus S-GE, with no significant difference in recurrence/reintervention rate (OR 0.54; p=0.22). In malignant GOO, CS (OR 1.90; p=0.12) and recurrence/reintervention rate (OR 0.68; p=0.50) were comparable, while overall AEs remained lower with EUS-GE (OR 0.26; p<0.01). Conclusions: In malignant GOO, EUS-GE provides comparable clinical efficacy to S-GE with fewer overall AEs. These data support EUS-GE as a preferred minimally invasive option in selected patients.

EUS-guided versus surgical gastroenterostomy for the management of malignant gastric outlet obstruction: A systematic review and meta-analysis

Maida, M;Vitello, A;
2026-01-01

Abstract

Background and Aims: Gastric outlet obstruction (GOO) is a late complication of several malignancies, markedly impairing quality of life. Surgical gastroenterostomy (S-GE) has long been the palliative standard, but outcomes are variable and morbidity remains considerable. Endoscopic ultrasound-guided gastroenterostomy (EUS-GE) has emerged as a minimally invasive alternative. We conducted a systematic review and meta-analysis comparing EUS-GE and S-GE, with a specific focus on malignant GOO. Methods: MEDLINE, Embase, Scopus, and the Cochrane Library were searched through September 2025. Eligible studies directly compared EUS-GE and S-GE and reported clinical success (CS), adverse events (AEs), severe AEs, and recurrence/reintervention. Pooled odds ratios (OR) with 95% confidence intervals (CI) were calculated using random-effects models. Results: Thirteen studies (2 RCTs, 11 retrospective; 1,611 patients) were analyzed. Overall, EUS-GE achieved higher CS (OR 2.69; p=0.007), fewer AEs (OR 0.21; p<0.001) and severe AEs (OR 0.54; p=0.05) versus S-GE, with no significant difference in recurrence/reintervention rate (OR 0.54; p=0.22). In malignant GOO, CS (OR 1.90; p=0.12) and recurrence/reintervention rate (OR 0.68; p=0.50) were comparable, while overall AEs remained lower with EUS-GE (OR 0.26; p<0.01). Conclusions: In malignant GOO, EUS-GE provides comparable clinical efficacy to S-GE with fewer overall AEs. These data support EUS-GE as a preferred minimally invasive option in selected patients.
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11387/208714
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact